leisure time -WSS

leisure time

author：focus 2025-09-28 23:30:40 - browse：897

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

focus

WSS

Will Ozempic

Studies point to risks of excluding people with obesity from drug trials

Solve the antibiotic resistance crisis with preventive drugs

STAT Summit: GSK CEO on pharma giant's new direction

HHS leader on health, climate change and biopharma emissions

Senate committee scrutinizes Medicare Advantage brokers

focus

leisure time

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Why health workers in Gaza are injured or die at high rates

The high cost of giving birth even with insurance

FDA approves Moderna’s RSV vaccine, its second licensed product

ChatGPT in medicine: STAT answers readers' burning questions

STAT Summit: GSK CEO on pharma giant's new direction

In age of alternative facts, a scholarly course on calling out crap

ASCO Takeaways: Winners, snoozers, and the art of cancer care

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Summit: Biotech founders on deal

hotspot

An outdated Medicare rule harms dementia patients with anxiety

Beam Therapeutics to lay off 20% of its staff, re

How CO2 helps viruses stay alive longer in the air

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Elevance PBM president out as customers face prescription chaos

FDA gives detailed accounting of AI

hotspot

focus

explore

explore